Fig. 5.
Effect of Lym-2 and ChCLL-1 treatment on the survival of RL bearing SCID mice. SCID mice received RL B cell lymphomas as described in Materials and Methods. Two days after IP tumor inoculation of 5 × 106 cells, the mice were injected with Lym-2 (▿) (2 μg), chCLL-1-γ (□) (2 μg), or mouse IgG1 (○) (2 μg) IP every other day for 20 days for a total of 10 injections. The mice were then monitored for tumor growth and survival. Lym-2 treatment and ChCLL-1 treatment significantly (P < .05) improved the survival of tumor-bearing mice compared with the isotype control. There were no significant differences in survival between Lym-2– and ChCLL-1–treated recipients.
